Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvogen's Lotus Secures Deal With Fuji To Bolster Asia Presence

Executive Summary

Alvogen’s Taiwanese subsidiary Lotus has confirmed a cross-investment partnership with Fuji that will strengthen the firms’ commercial platform in Japan and other key Asian pharmaceutical markets.

You may also be interested in...



Alvotech And Fuji Pharma Broaden Biosimilar Alliance In Japan

Longtime partners Alvotech and Fuji Pharma – the latter being a minority shareholder in the Icelandic firm – have extended their existing biosimilars partnership in Japan, as Alvotech continues to make strategic moves across the globe.

Alvogen’s Lotus Picks Up Darbepoetin Alfa Rights In Asia

Lotus Pharmaceuticals has expanded its biosimilar pipeline to five by bringing in rights in Taiwan and South East Asia markets to Chong Kun Dang Pharmaceutical’s biosimilar of Kyowa Kirin’s Nesp (darbepoetin alfa).

Alvogen Expands In CEE With Exeltis Portfolio

Alvogen has struck a deal with Insud’s Exeltis to gain rights to 23 women’s healthcare brands in Russia, Ukraine and Kazakhstan.

Related Content

Topics

UsernamePublicRestriction

Register

GB140182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel